Related Experiment Videos
How are the sub-unit pertussis vaccines to be evaluated?
1Department of Community Medicine, Manchester University Medical School, UK.
Epidemiology and Infection
|October 1, 1987
Summary
New whooping cough subunit vaccines aim to improve safety and uptake. This paper outlines trial designs and expected challenges for evaluating these improved pertussis vaccines.
Area of Science:
- Immunology
- Vaccinology
- Epidemiology
Background:
- The current whole-cell whooping cough vaccine in the UK, available since the 1950s, suffers from poor uptake due to neurotoxicity concerns.
- This low vaccine uptake has led to recurrent, significant epidemics of pertussis (whooping cough), causing substantial illness and death.
Purpose of the Study:
- To propose a framework for evaluating novel component (sub-unit) whooping cough vaccines.
- To outline the organizational structure for conducting clinical trials of these new vaccines.
- To identify potential challenges in the evaluation and implementation of subunit pertussis vaccines.
Main Methods:
- Discussion of trial design principles for vaccine efficacy and safety studies.
- Consideration of logistical and organizational aspects for large-scale field trials.
- Analysis of potential immunological and epidemiological challenges.
Main Results:
- Component vaccines, focusing on protective antigens, offer a potential solution to the safety concerns of older vaccines.
- Field testing and evaluation methodologies need to be robust to assess efficacy and safety accurately.
- Anticipation of challenges related to regulatory approval, manufacturing, and public acceptance.
Conclusions:
- Subunit whooping cough vaccines represent a promising advancement over older whole-cell formulations.
- Careful planning and execution of clinical trials are crucial for the successful evaluation of these new vaccines.
- Addressing the historical issues of vaccine safety and efficacy is paramount to improving pertussis control and preventing epidemics.